Intracranial Cns Malignancies

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2019-04-16
Clinical Trial Update: Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors [Phase 2]
Phase 2 clinical trial update evaluating apatinib for recurrent or refractory intracranial CNS malignant tumors has been completed.